Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose propofol vs ketamine vs propofol-ketamine for prevention of cough and laryngospasm after extubation
IRCT20251215068344N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cough and laryngismus comparing Low-dose propofol, Low-dose ketamine and Low-dose propofol + ketamine (3 arms). Primary endpoints: Incidence of cough after extubation and Incidence of laryngospasm after extubation. Started Mar 2025; status: completed.
02
Drugs
propofolketamine
03
Conditions
coughlaryngismus
Beyond the preview
Go deeper on IRCT20251215068344N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251215068344N1.